Potential therapeutic strategies to target SPAG5 in adult AML include the use of SPAG5 inhibitors to disrupt SPAG5 interactions, combination therapy with other targeted drugs such as CDK1 and MDM2 inhibitors, the exploration of immunotherapy approaches targeting SPAG5-expressing cells, the use of gene editing to knock down SPAG5 expression, and the screening of natural compounds that inhibit SPAG5 or its interactions. This evidence concerns the gene SPAG5 and acute myeloid leukemia.